Literature DB >> 33106302

Pneumocystis jirovecii pneumonia prophylaxis in a 42-year-old woman on immunosuppressive therapy.

Sheliza Halani1, Nisha Andany1, Rupal Shah2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33106302      PMCID： PMC7577577          DOI： 10.1503/cmaj.200846

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  11 in total

Review 1.  Update on the diagnosis and treatment of Pneumocystis pneumonia.

Authors:  Eva M Carmona; Andrew H Limper
Journal:  Ther Adv Respir Dis       Date:  2010-08-24       Impact factor: 4.031

Review 2.  Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients.

Authors:  Anat Stern; Hefziba Green; Mical Paul; Liat Vidal; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2014-10-01

Review 3.  Update on pulmonary Pneumocystis jirovecii infection in non-HIV patients.

Authors:  A Roux; F Gonzalez; M Roux; M Mehrad; J Menotti; J-R Zahar; V-X Tadros; E Azoulay; P-Y Brillet; F Vincent
Journal:  Med Mal Infect       Date:  2014-03-11       Impact factor: 2.152

4.  Accuracy of serum LDH elevation for the diagnosis of Pneumocystis jiroveci pneumonia.

Authors:  Monika N Vogel; Patrick Weissgerber; Benjamin Goeppert; Jürgen Hetzel; Mignon Vatlach; Claus D Claussen; Marius Horger
Journal:  Swiss Med Wkly       Date:  2011-04-29       Impact factor: 2.193

5.  Risk factors for Pneumocystis carinii pneumonia in patients with polymyositis/dermatomyositis or systemic lupus erythematosus.

Authors:  A Kadoya; J Okada; Y Iikuni; H Kondo
Journal:  J Rheumatol       Date:  1996-07       Impact factor: 4.666

Review 6.  Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials.

Authors:  Hefziba Green; Mical Paul; Liat Vidal; Leonard Leibovici
Journal:  Mayo Clin Proc       Date:  2007-09       Impact factor: 7.616

7.  Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy.

Authors:  S H Yale; A H Limper
Journal:  Mayo Clin Proc       Date:  1996-01       Impact factor: 7.616

8.  Pneumocystis jirovecii pneumonia in patients with or without AIDS, France.

Authors:  Antoine Roux; Emmanuel Canet; Sandrine Valade; Florence Gangneux-Robert; Samia Hamane; Ariane Lafabrie; Daniéle Maubon; Anne Debourgogne; Soléne Le Gal; Fréderic Dalle; Marion Leterrier; Dominique Toubas; Christelle Pomares; Anne Pauline Bellanger; Julie Bonhomme; Antoine Berry; Isabelle Durand-Joly; Denis Magne; Denis Pons; Christophe Hennequin; Eric Maury; Patricia Roux; Élie Azoulay
Journal:  Emerg Infect Dis       Date:  2014-09       Impact factor: 6.883

9.  Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids.

Authors:  Jun Won Park; Jeffrey R Curtis; Jinyoung Moon; Yeong Wook Song; Suhnggwon Kim; Eun Bong Lee
Journal:  Ann Rheum Dis       Date:  2017-11-01       Impact factor: 19.103

10.  The RIG-I pathway is involved in peripheral T cell lymphopenia in patients with dermatomyositis.

Authors:  Lu Zhang; Qisheng Xia; Wenli Li; Qinglin Peng; Hanbo Yang; Xin Lu; Guochun Wang
Journal:  Arthritis Res Ther       Date:  2019-05-29       Impact factor: 5.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.